🔥 Inflammation Deep Dive

What this panel can settle, and by what logic

Ten markers, and the panel earns its price by answering two questions the single hs-CRP everyone already has cannot: is the inflammation persistent, and is it metabolic.

1. hs-CRP (High-Sensitivity C-Reactive Protein) with ESR (Sed Rate) and Fibrinogen Activity separates a spike from a state. CRP doubles within hours of a stimulus and clears within days; the sedimentation rate and fibrinogen move slowly and stay up. Three markers raised together on one draw is a persistent process; CRP alone is a bad week.
2. Ferritin read against hs-CRP (High-Sensitivity C-Reactive Protein) is the pairing that prevents the commonest misreading on the panel. Ferritin is an acute-phase protein, so it rises with inflammation independently of iron stores — the reason the BRINDA method exists Luo 2023. A ferritin of 500 ng/mL with metabolic syndrome and a mild CRP is usually metabolic hyperferritinemia, a defined entity that is not iron overload Valenti 2023.
3. HbA1c (Hemoglobin A1c) and Uric Acid are on an inflammation panel on purpose. Adipose tissue and hyperglycemia are among the commonest drivers of a chronically raised CRP in people with no other disease, and HbA1c is the marker that shows it — while remembering that HbA1c is partly a red-cell measurement and shifts with anything that changes red-cell survival Chen 2022.
4. Homocysteine is the one marker here that names its own treatment. A raised value points at B12 or folate status and responds to them, which is the mechanism the VITACOG trial used Smith 2010.

What it cannot settle, and what would

It cannot tell you where the inflammation is. hs-CRP is a quantity, not a location. Infection, autoimmunity, adiposity, periodontal disease, a recent hard training block and an occult malignancy all raise it and this panel cannot separate them. Everything that localizes inflammation is imaging, endoscopy or a specific antibody.

Lp-PLA2 Activity and Myeloperoxidase (MPO) predict risk without being worth treating, and that distinction is the most expensive thing on this page. Lp-PLA2 activity was a genuine risk marker in stable coronary disease, with a hazard ratio of 1.50 for the primary composite endpoint across thirds — and darapladib cut median Lp-PLA2 activity by 65% without improving outcomes Wallentin 2016. A high result here changes your risk estimate, not your treatment.

A high Uric Acid is not an indication to treat. Asymptomatic hyperuricemia predicts gout and tracks with metabolic disease, but the finding on this panel is a reason to look at the metabolic markers beside it rather than to start a urate-lowering drug.

And a completely clean panel does not exclude the thing most people bought it for. Coronary risk is driven mainly by apolipoprotein-B-containing particles, smoking, blood pressure and glycemia — the modifiable factors that accounted for most of the population-attributable risk of a first myocardial infarction across 52 countries Yusuf 2004. Normal inflammatory markers do not offset a high ApoB (Apolipoprotein B).

Draw conditions that decide whether the money is wasted

Every marker on this panel is movable by the fortnight before the draw, which makes timing unusually decisive here.

1. At least 2 weeks after an infection or a vaccination. Both raise CRP, ESR, fibrinogen and ferritin at once, which is the exact pattern the panel is trying to detect. There is no correction for this — the draw is simply wasted.
2. 72 hours clear of a hard session, and be honest about training load. Acute exercise provokes an acute-phase response; regular training lowers resting CRP, with significant reductions in 11 of 25 aerobic trials in one review Michigan 2011. A marathon on Sunday and a panel on Monday measures the marathon.
3. Fast 9 to 12 hours. HbA1c (Hemoglobin A1c) does not need it, but the fasting state keeps this panel comparable with the metabolic markers you will inevitably order next.
4. Do not stop a statin, aspirin or anti-inflammatory to get a "true" reading. The number you want is the one you are living with; a drug-free CRP describes a person you are not.

How you would know it answered your question, and what each pattern means next

Five patterns, with the interval each one earns and why.

• hs-CRP (High-Sensitivity C-Reactive Protein) above 3 mg/L on two draws 4 weeks apart: persistent, and the productive follow-up is metabolic rather than immunological — ApoB (Apolipoprotein B), Fasting Insulin and HbA1c (Hemoglobin A1c) Yusuf 2004.
• Ferritin 300 to 1,000 ng/mL with a raised CRP and central adiposity: read it as metabolic hyperferritinemia and treat the metabolism Valenti 2023. Repeat at 6 months; if it rises with a normal CRP, work through the hyperferritinemia differential instead Anders 2026.
• Homocysteine above 10 µmol/L: check Vitamin B12, Methylmalonic Acid (MMA) and Folate, Serum and correct what is low. Retest at 12 weeks, which is roughly the interval over which B-vitamin repletion moved homocysteine in trial conditions Smith 2010.
• Lp-PLA2 Activity or Myeloperoxidase (MPO) raised in isolation: do not chase it. There is no treatment that improves outcomes by lowering these numbers Wallentin 2016; spend the follow-up money on ApoB (Apolipoprotein B) and Lp(a) instead.
• Everything normal: the panel has excluded systemic inflammation as the explanation. Do not repeat it inside 12 months — CRP's within-person variability means a second normal panel tells you nothing the first did not Michigan 2011.

Sources read for these sections

• Wallentin L, et al. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association 2016 · PMID 27329448
• Luo H, et al. A Practical Guide to Adjust Micronutrient Biomarkers for Inflammation Using the BRINDA Method. Journal of Nutrition 2023 · PMID 36792034
• Valenti L, et al. Consensus Statement on the definition and classification of metabolic hyperferritinaemia. Nature Reviews Endocrinology 2023 · PMID 36805052
• Anders MM, Sorda JA. [Differential diagnosis of hyperferritinemia]. Medicina (Buenos Aires) 2026 · PMID 41961610
• Chen Z, et al. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Experimental and Therapeutic Medicine 2022 · PMID 36382101
• Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 · PMID 15364185
• Michigan A, Johnson TV, Master VA. Review of the relationship between C-reactive protein and exercise. Molecular Diagnosis and Therapy 2011 · PMID 22047154
• Smith AD, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010 · PMID 20838622